Insider transactions at AtriCure are not encouraging. However, insiders' share ownership suggests some alignment. Maggie Yuen's sale at a price above the current share price may not reflect insider confidence.

Investors forecast sustained strong revenue performance from AtriCure, reflected in a high P/S ratio. Shareholders currently show confidence in the company's future revenue, bolstering its shares. The high P/S ratio is deemed appropriate due to robust future revenues.

The lack of insider purchasing and ample selling in the past year could be red flags for potential investors in AtriCure. Despite high insider ownership, absence of buying is unsettling. Additionally, unspecified risks and concerns for AtriCure are noteworthy.